Transcriptional Regulation of GATA-1
Lead Research Organisation:
University of Oxford
Abstract
A common cause of severe anaemia that can progress to leukaemia is known as myelodysplasia. In this condition blood cell precursors are made but fail to mature properly and do not function appropriately. Understanding this disorder depends on knowing how blood cells are normally made and mature in the bone marrow.||Our interest has focused on one critical factor that is required in this process, which is called GATA-1. GATA-1 co-ordinates many aspects of the normal maturation programme of blood and we wish to aspects of it biology.
Technical Summary
A key biological question, relevant to all differentiating tissues, is how multiple cell types arise from a pluripotential cell. When this process is perturbed it leads to human disease. We are using the haemopoietic system to study this question as it provides a good scientific and clinical model. Our laboratory is focused on how the erythroid and megakaryocytic lineages are specified and mature from a progenitor cell. Our particular interest is the role key transcription factors play in these processes. In particular, the zinc-finger transcription factor GATA-1 is absolutely required for the proper maturation of both the red cell and megakaryocyte lineages. In addition, GATA-1 expression is initiated in early haematopoietic progenitor at low level but then is restricted to principally erythroid and megakaryocytic cells where it is expressed at high level.||Our aim is to understand the molecular mechanisms that result in the tissue- and developmental- specific pattern of expression. As a consequence of these studies we hope to identify the transcriptional regulators that lie upstream of GATA-1 and thus help to specify the erythroid and megakaryocyte lineages.||Our approach to this problem is to try and identify all the cis-acting elements that are required for GATA-1 expression and the trans-acting factors that bind to them. We are identifying putative cis-elements in the GATA-1 locus by DNase I hypersensitivity analysis and by pin-pointing non-coding sequence that is conserved in evolution between mouse and human. Once putative cis-elements have been identified we are testing if they have function in stable cell transfection assays and in transgenic mice. Protein-DNA interactions at functionally important elements will be then be determined. Lastly, the functional importance of selected elements will be further examined by deleting them by homologous recombination in mice.
Organisations
- University of Oxford, United Kingdom (Lead Research Organisation)
- Cardiff University, United Kingdom (Collaboration)
- Imperial College London, United Kingdom (Collaboration)
- Barts Health NHS Trust, London (Collaboration)
- Stanford University, United States (Collaboration)
- Queen Elizabeth Hospital Birmingham (Collaboration)
People |
ORCID iD |
Paresh Vyas (Principal Investigator) |
Publications

Sekeres MA
(2022)
A phase 1b study of glasdegib + azacitidine in patients with untreated acute myeloid leukemia and higher-risk myelodysplastic syndromes.
in Annals of hematology

Josa-Culleré L
(2021)
A Phenotypic Screen Identifies a Compound Series That Induces Differentiation of Acute Myeloid Leukemia Cells In Vitro and Shows Antitumor Effects In Vivo
in Journal of Medicinal Chemistry

Dennis M
(2021)
A randomised evaluation of low-dose cytosine arabinoside (ara-C) plus tosedostat versus low-dose ara-C in older patients with acute myeloid leukaemia: results of the LI-1 trial.
in British journal of haematology


Bache I
(2020)
A shared somatic translocation involving CUX1 in monozygotic twins as an early driver of AMKL in Down syndrome.
in Blood cancer journal

Mussai F
(2013)
Acute myeloid leukemia creates an arginase-dependent immunosuppressive microenvironment
in Blood

Hanekamp D
(2020)
Applicability and reproducibility of acute myeloid leukaemia stem cell assessment in a multi-centre setting.
in British journal of haematology

Craddock C
(2021)
Augmented Reduced-Intensity Regimen Does Not Improve Postallogeneic Transplant Outcomes in Acute Myeloid Leukemia.
in Journal of clinical oncology : official journal of the American Society of Clinical Oncology


Ossenkoppele G
(2020)
BCL-2 Inhibitor and Conventional Chemotherapy Combinations for Acute Myeloid Leukemia: Shifting From the Unfit to the Fit Patient With AML.
in Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Description | NHSBT Non Executive Director |
Geographic Reach | National |
Policy Influence Type | Influenced training of practitioners or researchers |
Impact | Ensuring quality and safe provision of blood and organs - Stem cells for England. |
Description | NHSBT Non-Executive Director |
Geographic Reach | National |
Policy Influence Type | Influenced training of practitioners or researchers |
Impact | Ensuring quality and safe provision of blood and organs. |
Description | NHSBT Non-Executive Director |
Geographic Reach | National |
Policy Influence Type | Influenced training of practitioners or researchers |
Impact | Ensuring quality and safe provision of blood and organs - Stem cells for England. |
Description | 0011150 CF |
Amount | £241,600 (GBP) |
Organisation | University of Oxford |
Department | John Fell Fund |
Sector | Academic/University |
Country | United Kingdom |
Start | 11/2021 |
End | 09/2022 |
Description | 2009 Disease Team Award |
Amount | £2,200,000 (GBP) |
Organisation | Medical Research Council (MRC) |
Sector | Public |
Country | United Kingdom |
Start | 03/2010 |
End | 05/2014 |
Description | Amendment 4 Collaboration CyTOF Panels Mount Sinai |
Amount | £43,800 (GBP) |
Organisation | Bristol-Myers Squibb |
Department | Celgene |
Sector | Private |
Country | United States |
Start | 09/2019 |
End | 09/2022 |
Description | BD - Celgene Fellowship Agreement for Supat Thongjuea entitled "Single-Cell Computational Biology for Translational Medicine |
Amount | £519,623 (GBP) |
Organisation | Bristol-Myers Squibb |
Department | Celgene |
Sector | Private |
Country | United States |
Start | 11/2019 |
End | 10/2022 |
Description | BRC3 - Precision Medicine cluster funding |
Amount | £112,500 (GBP) |
Organisation | National Institute for Health Research |
Sector | Public |
Country | United Kingdom |
Start | 03/2019 |
End | 03/2020 |
Description | Blood Cancer UK - Programme Continuity Grant |
Amount | £300,000 (GBP) |
Organisation | Blood Cancer UK |
Sector | Charity/Non Profit |
Country | United Kingdom |
Start | 03/2020 |
End | 04/2024 |
Description | Celgene PhD Studentship |
Amount | £174,000 (GBP) |
Organisation | Bristol-Myers Squibb |
Department | Celgene |
Sector | Private |
Country | United States |
Start | 08/2010 |
End | 08/2013 |
Description | Celgene Translational Science Proposal |
Amount | £1,065,908 (GBP) |
Organisation | Bristol-Myers Squibb |
Department | Celgene |
Sector | Private |
Country | United States |
Start | 09/2019 |
End | 01/2023 |
Description | HIDI Award |
Amount | £25,000 (GBP) |
Organisation | National Institute for Health Research |
Sector | Public |
Country | United Kingdom |
Start | 07/2018 |
End | 07/2019 |
Description | Leukaemia Research Specialist Programme Grant 2008 |
Amount | £1,034,000 (GBP) |
Organisation | Leukaemia and Lymphoma Research |
Sector | Charity/Non Profit |
Country | United Kingdom |
Start | 06/2008 |
End | 07/2013 |
Description | MRC Molecular Haematology Unit Award |
Amount | £520,000 (GBP) |
Organisation | Medical Research Council (MRC) |
Sector | Public |
Country | United Kingdom |
Start | 03/2013 |
End | 03/2017 |
Description | Medical Research Council (MRC) - Molecular Haematology Unit Award |
Amount | £1,387,000 (GBP) |
Organisation | Medical Research Council (MRC) |
Sector | Public |
Country | United Kingdom |
Start | 03/2017 |
End | 04/2022 |
Description | Oxford Comprehensive Biomedical Research Centre |
Amount | £60,000 (GBP) |
Organisation | National Institute for Health Research |
Sector | Public |
Country | United Kingdom |
Start | 03/2018 |
End | 04/2022 |
Description | WIMM - Lymphoma Biobank |
Amount | £44,500 (GBP) |
Organisation | Oxford University Hospitals NHS Foundation Trust |
Sector | Academic/University |
Country | United Kingdom |
Start | 11/2021 |
End | 10/2022 |
Description | WIMM - TAL Wolfson Donation |
Amount | £750,000 (GBP) |
Organisation | The Wolfson Foundation |
Sector | Charity/Non Profit |
Country | United Kingdom |
Start | 05/2021 |
End | 05/2023 |
Description | WIMM LadyTata- A Groom |
Amount | £75,000 (GBP) |
Organisation | Lady Tata Memorial Trust |
Sector | Charity/Non Profit |
Country | United Kingdom |
Start | 09/2021 |
End | 09/2023 |
Description | WIMM-Celgene F'ship 21-2 |
Amount | £543,000 (GBP) |
Organisation | Bristol-Myers Squibb |
Department | Celgene |
Sector | Private |
Country | United States |
Start | 03/2021 |
End | 10/2022 |
Description | Development of novel therapeutic anti-leuakemia stem cell antibodies |
Organisation | Barts Health NHS Trust |
Department | Department of Haematology |
Country | United Kingdom |
Sector | Hospitals |
PI Contribution | We lead the UK component of this transatlantic collaboration. The basic science and translational studies are driven from Oxford. |
Collaborator Contribution | It has provided access to novel technologies and unpublished dataAccess to novel therapies. Access to patient samples. Access to laboratory collaborations. Acquisition of biological samples and clinical data. Acquisition of biological samples and clinical data |
Impact | Grants 2009 £2.2 M MRC Disease Team Award Publications (PubMed ID numbers below): 19664981 19546437 19644143 |
Start Year | 2007 |
Description | Development of novel therapeutic anti-leuakemia stem cell antibodies |
Organisation | Cardiff University |
Department | Haematology |
Country | United Kingdom |
Sector | Academic/University |
PI Contribution | We lead the UK component of this transatlantic collaboration. The basic science and translational studies are driven from Oxford. |
Collaborator Contribution | It has provided access to novel technologies and unpublished dataAccess to novel therapies. Access to patient samples. Access to laboratory collaborations. Acquisition of biological samples and clinical data. Acquisition of biological samples and clinical data |
Impact | Grants 2009 £2.2 M MRC Disease Team Award Publications (PubMed ID numbers below): 19664981 19546437 19644143 |
Start Year | 2007 |
Description | Development of novel therapeutic anti-leuakemia stem cell antibodies |
Organisation | Queen Elizabeth Hospital Birmingham |
Country | United Kingdom |
Sector | Hospitals |
PI Contribution | We lead the UK component of this transatlantic collaboration. The basic science and translational studies are driven from Oxford. |
Collaborator Contribution | It has provided access to novel technologies and unpublished dataAccess to novel therapies. Access to patient samples. Access to laboratory collaborations. Acquisition of biological samples and clinical data. Acquisition of biological samples and clinical data |
Impact | Grants 2009 £2.2 M MRC Disease Team Award Publications (PubMed ID numbers below): 19664981 19546437 19644143 |
Start Year | 2007 |
Description | Development of novel therapeutic anti-leuakemia stem cell antibodies |
Organisation | Stanford University |
Country | United States |
Sector | Academic/University |
PI Contribution | We lead the UK component of this transatlantic collaboration. The basic science and translational studies are driven from Oxford. |
Collaborator Contribution | It has provided access to novel technologies and unpublished dataAccess to novel therapies. Access to patient samples. Access to laboratory collaborations. Acquisition of biological samples and clinical data. Acquisition of biological samples and clinical data |
Impact | Grants 2009 £2.2 M MRC Disease Team Award Publications (PubMed ID numbers below): 19664981 19546437 19644143 |
Start Year | 2007 |
Description | Downs Syndrome associated preleukaemia and leukaemia |
Organisation | Imperial College London |
Department | Centre for Haematology |
Country | United Kingdom |
Sector | Academic/University |
PI Contribution | We provide the majority of the research effort in this collaborative programme. We study the molecular and cellular basis of leukaemia using patient samples and mouse models that we are generating. |
Collaborator Contribution | We have a joint programme of work including a joint LLR Programme grant |
Impact | Grants 2008 Leukaemia Research 5-year Programme Grant, £1.03 M Publications (PubMed ID below): 19594743 18242315 18689547 18059480 18625887 17804520 17644747 17224656 17064858 |
Start Year | 2006 |
Description | Advising LLR to identify and prioritise the needs of blood cancer patients |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | Yes |
Geographic Reach | Local |
Primary Audience | Public/other audiences |
Results and Impact | 1. Helped fund raising. 2. Helped public awareness 3. Helped improve public advocacy 1. £15 000 were raised. 2. I have been asked to write booklet for patients with Acute Myeloid Leukaemia. 3. I have been asked to give a talk to members of Parliament. |
Year(s) Of Engagement Activity | 2014 |
Description | Hosted Work Experience Programme |
Form Of Engagement Activity | Participation in an open day or visit at my research institution |
Part Of Official Scheme? | No |
Geographic Reach | Local |
Primary Audience | Other audiences |
Results and Impact | Run a session on haematology for students in the MRC WIMM work experience programme. Included go fish game, activities on gene expression using legos and microscopy and leukaemia diagnosis |
Year(s) Of Engagement Activity | 2019 |
Description | MRC Festival 2019 on Cancer immunotherapy - Grigore |
Form Of Engagement Activity | Participation in an activity, workshop or similar |
Part Of Official Scheme? | No |
Geographic Reach | Local |
Primary Audience | Public/other audiences |
Results and Impact | Part of working group that developed activities for MRC Festival 2019 on Cancer immunotherapy |
Year(s) Of Engagement Activity | 2019 |
Description | OXFORD & NATIONWIDE SUPPORT GROUP MEETING - MDS UK Members |
Form Of Engagement Activity | Participation in an activity, workshop or similar |
Part Of Official Scheme? | No |
Geographic Reach | National |
Primary Audience | Patients, carers and/or patient groups |
Results and Impact | Speaker at OXFORD & NATIONWIDE SUPPORT GROUP MEETING - MDS UK Members |
Year(s) Of Engagement Activity | 2021 |
Description | Patient Support Group |
Form Of Engagement Activity | Participation in an activity, workshop or similar |
Part Of Official Scheme? | No |
Geographic Reach | Local |
Primary Audience | Patients, carers and/or patient groups |
Results and Impact | Giving support and advice to patients, families and carers. |
Year(s) Of Engagement Activity | 2019 |
Description | Science Week |
Form Of Engagement Activity | A formal working group, expert panel or dialogue |
Part Of Official Scheme? | Yes |
Geographic Reach | Local |
Primary Audience | Public/other audiences |
Results and Impact | Oxford Science Week is held annually to an audience of scientists and the general public. Good feedback from schools |
Year(s) Of Engagement Activity | 2006,2007,2008,2009,2014 |
Description | Science in the supermarket, MRC Festival 2019 - Douzi & Grigore |
Form Of Engagement Activity | Participation in an activity, workshop or similar |
Part Of Official Scheme? | No |
Geographic Reach | Local |
Primary Audience | Public/other audiences |
Results and Impact | Science in the supermarket, MRC Festival 2019 |
Year(s) Of Engagement Activity | 2019 |
Description | Student Presentations |
Form Of Engagement Activity | Participation in an activity, workshop or similar |
Part Of Official Scheme? | Yes |
Geographic Reach | Local |
Primary Audience | Postgraduate students |
Results and Impact | Final year students present their work to the members of the Weatherall Institute of Molecular Medicine. This presentation day is held annually. Improved student training. |
Year(s) Of Engagement Activity | 2006,2007,2008,2009,2010 |